Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Bill who wrote (1515559)	1/23/2025 5:00:32 PM
From: koan	Read Replies (1) \| Respond to of 1571788

You are the one who is not representing the importance, or TRUTH of 14087! " This provision of the IRA was a HUGE step forward to lowering costs and easing stress on family budgets for working Americans, and it also helped lower government spending and reduce deficits. How about giving an honest assessment of what rescinding it does!!? Bidin finally gave the OK for Medicare to negotiate with pharmaceutical companies over prices the federal government paid for drugs to LOWER them, and--- Trump fucking canceled that! Don't you wonder why? Or do you know why and want to lie about it? " In 2022, the Inflation Reduction Act (IRA) gave Medicare the right – for the first time in its history – to negotiate with pharmaceutical companies over prices the federal government paid for drugs in Medicare Part D (the part of Medicare that provides insurance coverage for prescription drugs). " Rescind EO 14087 Lowering Prescription Drug Prices for Americans White House January 20, 2025 On January 20, 2025, President Trump rescinded the Biden administration’s Executive Order 14087: Lower Prescription Drug Prices for Americans. In 2022, the Inflation Reduction Act (IRA) gave Medicare the right – for the first time in its history – to negotiate with pharmaceutical companies over prices the federal government paid for drugs in Medicare Part D (the part of Medicare that provides insurance coverage for prescription drugs). This provision of the IRA was a huge step forward to lowering costs and easing stress on family budgets for working Americans, and it also helped lower government spending and reduce deficits. EO 14087 directed the Department of Health and Human Services (HHS) to consider additional actions that could reduce prescription drug costs. In response to the EO, the HHS put forward several models of improved affordability and access to prescription drugs that policymakers could implement. It included proposals to institute a $2 co-payment for generic prescription drugs across Medicare Part D, and to help state governments in their own negotiations with drug companies over prices in Medicaid. If the recommendations of the EO were advanced by the Trump administration rather than rescinded, further progress in reducing working families’ cost-of-living could have been made.